Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...
Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s ...
Metsera has technologies and drug candidates intended to improve on these limitations. With key clinical trial readouts expected this year, the company took its story to investors through an IPO.
Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...
Dealbreaker on MSN27d
Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1sDrugs that activate the GLP-1 receptor transformed the treatment of obesity, but biotech company Metsera contends that ...
In other recent news, Metsera Inc has made significant strides with its initial public offering (IPO), which opened 42% higher than its offering price. The company initially set its IPO at $18.00 ...
In other recent news, Metsera Inc has made significant strides with its initial public offering (IPO), which opened 42% higher than its offering price. The company initially set its IPO at $18.00 per ...
Notably, Metsera (MTSR, NC), an emerging player in the obesity market, saw its stock soar by 47% on its first trading day. Merger and acquisition (M&A) activities in the biotech space were few but ...
Last September, another obesity-focused biotech, BioAge, completed an upsized IPO that raised $198 million, after the number of shares on offer was hiked by 40%. Metsera's lead asset is MET-097i ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback